GO:0110077 vesicle-mediated intercellular transport: Extracellular Vesicle Signaling, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0110077 vesicle-mediated intercellular transport describes the movement of substances between cells inside extracellular vesicles, where cargo is enclosed in the vesicle lumen or embedded in the vesicle membrane.
• This process is a fundamental mode of intercellular communication that can reprogram recipient cells and shape the tumor microenvironment in breast, bladder, lung, cervical, and gastric cancers [1,3,4,5,6].
• Vesicle-mediated transport delivers diverse cargoes including proteins such as Hsp70 and ALIX, long non-coding RNAs such as ELNAT1, and ESCRT-III components [2,5,7].
• SUMOylation and other post-translational modifications regulate the sorting and transmission of vesicular cargo, directly influencing metastatic spread.
• Vesicle-mediated transport-related gene signatures have prognostic value and can predict immunotherapy response and drug sensitivity in multiple cancer types [4,6].
• CRISPR knockout, knock-in, point-mutation, and overexpression models are powerful tools for dissecting the causal roles of vesicle-mediated transport genes in disease [1,2,4].
Description
Vesicle-mediated intercellular transport (GO:0110077) is a biological process in which transported substances are moved in extracellular vesicles between cells, with the transported material either enclosed within the vesicle lumen or located in the extracellular vesicle membrane. This definition places the process at the intersection of cell biology, membrane trafficking, and intercellular communication, distinguishing it from intracellular vesicle trafficking by its explicit focus on transfer between distinct cells. The term captures a wide range of cargoes, from membrane-anchored receptors and heat shock proteins to long non-coding RNAs and ESCRT machinery components [2,5,7]. Over the past decade, vesicle-mediated intercellular transport has emerged as a central mechanism in cancer progression and metastasis. Tumor-derived apoptotic extracellular vesicles can promote metastasis and stemness in lung adenocarcinoma, illustrating how vesicle cargo can reprogram recipient cells toward a more aggressive phenotype. In breast cancer, extracellular vesicle-mediated transport reprograms the tumor microenvironment to favor progression and metastasis. Similar observations have been made in bladder cancer, where SUMOylation promotes extracellular vesicle-mediated transmission of the long non-coding RNA ELNAT1 and drives lymph node metastasis. Beyond oncology, the process is relevant to any field concerned with how cells exchange information without direct cell-cell contact. Small extracellular vesicle-mediated delivery of Hsp70 enhances adriamycin resistance in breast cancer cells, showing that vesicle transport can also modulate therapeutic response. The growing recognition that vesicle-mediated signaling is not merely a disposal route but an active communication system has prompted calls to rethink how we model extracellular vesicle signaling in health and disease. For researchers, GO:0110077 provides a precise ontological handle for annotating genes, designing functional experiments, and interpreting multi-omic data in the context of intercellular transfer [4,6].
vesicle-mediated intercellular transport At A Glance
| GO ID | GO:0110077 |
|---|---|
| GO term | vesicle-mediated intercellular transport |
| Ontology | biological_process |
| Synonym | endosomal trafficking |
| Definition | A cellular transport process in which transported substances are moved in extracellular vesicles between cells; transported substances are enclosed in the vesicle lumen or located in the extracellular vesicle membrane. |
| Major function | Intercellular transfer of proteins, RNAs, and membrane components via extracellular vesicles |
| Cargo location | Vesicle lumen or extracellular vesicle membrane |
| Representative cargoes | Hsp70, ALIX, ESCRT-III, lncRNA ELNAT1 |
| Disease relevance | Cancer metastasis, therapy resistance, tumor microenvironment reprogramming |
What Is GO:0110077?
In our own words, GO:0110077 vesicle-mediated intercellular transport is the process by which substances are carried from one cell to another inside extracellular vesicles. The transported substances are either packaged within the lumen of the vesicle or associated with the extracellular vesicle membrane. This distinguishes the term from general vesicle trafficking by emphasizing transfer between cells rather than within a single cell, and it encompasses the biogenesis, release, and uptake of vesicles that mediate this intercellular exchange.
Why Is vesicle-mediated intercellular transport Important in Cell Biology?
Vesicle-mediated intercellular transport matters because it provides a mechanism for cells to exchange proteins, RNAs, and membrane-associated signals without direct cell-cell contact, thereby shaping tissue-level behavior in cancer and other diseases [3,8]. In breast cancer, extracellular vesicle-mediated transport actively reprograms the tumor microenvironment to support progression and metastasis. In lung adenocarcinoma, tumor-derived apoptotic extracellular vesicles promote metastasis and stemness, demonstrating that vesicle cargo can drive aggressive phenotypes in recipient cells. In bladder cancer, SUMOylation-dependent vesicle-mediated transmission of the lncRNA ELNAT1 promotes lymph node metastasis, linking a specific post-translational modification to vesicle cargo sorting and disease outcome. Small extracellular vesicle-mediated Hsp70 delivery enhances adriamycin resistance in breast cancer, showing that vesicle transport can directly modulate therapeutic efficacy. More broadly, vesicle-mediated transport-related gene signatures have prognostic significance in gastric and cervical cancers and can predict immunotherapy response and drug sensitivity [4,6]. These findings establish GO:0110077 as a clinically relevant process and a rich source of candidate biomarkers and therapeutic targets.
• Provides a contact-independent route for intercellular communication via extracellular vesicles.
• Promotes metastasis and stemness in lung adenocarcinoma through tumor-derived apoptotic extracellular vesicles.
• Reprograms the tumor microenvironment to favor breast cancer progression and metastasis.
• Enables SUMOylation-dependent transfer of lncRNA ELNAT1 and drives lymph node metastasis in bladder cancer.
• Enhances adriamycin resistance in breast cancer via small extracellular vesicle-mediated Hsp70 delivery.
• Supports cytokinesis-associated transport of ALIX and ESCRT-III to the intercellular bridge.
• Vesicle-mediated transport-related gene signatures predict prognosis in gastric cancer.
• Vesicle-mediated transport-related genes predict immunotherapy response and drug sensitivity in cervical cancer.
• Offers candidate biomarkers and therapeutic targets across multiple cancer types [4,6].
• Requires careful experimental modeling because vesicle signaling is complex and context-dependent.
What Happens During vesicle-mediated intercellular transport?
Cargo selection and vesicle biogenesis
In simple terms: The cell decides which molecules to package into vesicles.
Vesicle-mediated intercellular transport begins with the selection of cargo and the formation of extracellular vesicles. Cargo can include membrane proteins, cytosolic proteins recruited into the vesicle lumen, and long non-coding RNAs. In bladder cancer, SUMOylation promotes the packaging and extracellular vesicle-mediated transmission of the lncRNA ELNAT1, illustrating how post-translational modification influences cargo selection. In breast cancer, small extracellular vesicles carry Hsp70 for intercellular delivery, showing that stress proteins can be actively sorted into vesicles. The ESCRT machinery, including ALIX and ESCRT-III, participates in vesicle-related trafficking events and is itself transported to the intercellular bridge during cytokinesis.
Vesicle release and extracellular transit
In simple terms: The vesicle leaves the donor cell and travels outside the cell.
Once formed, vesicles are released from the donor cell into the extracellular space. This step is essential for the transported substances to reach recipient cells. Tumor-derived apoptotic extracellular vesicles are released and can subsequently act on neighboring or distant cells to promote metastasis and stemness in lung adenocarcinoma. In breast cancer, extracellular vesicles released into the tumor microenvironment mediate transport that reprograms recipient cells and supports progression and metastasis. The concept of vesicle-mediated signaling as an active communication system, rather than passive debris, has been emphasized in recent re-evaluations of extracellular vesicle biology.
Uptake by recipient cells
In simple terms: Another cell takes in the vesicle and its cargo.
Recipient cells internalize extracellular vesicles, allowing the transported substances to exert effects in a new cellular context. Small extracellular vesicle-mediated Hsp70 delivery to breast cancer cells enhances adriamycin resistance, demonstrating functional transfer of a protein cargo into recipient cells. In bladder cancer, extracellular vesicle-mediated transmission of ELNAT1 delivers the lncRNA to recipient cells and promotes lymph node metastasis. In lung adenocarcinoma, tumor-derived apoptotic extracellular vesicles act on recipient cells to promote metastasis and stemness. These examples show that uptake is not merely a clearance mechanism but a route for functional intercellular transfer.
Functional consequences in recipient cells
In simple terms: The delivered cargo changes how the recipient cell behaves.
After uptake, vesicle cargo can alter gene expression, signaling, and phenotype in recipient cells. Extracellular vesicle-mediated transport in breast cancer reprograms the tumor microenvironment to be conducive to progression and metastasis. In lung adenocarcinoma, apoptotic extracellular vesicle-mediated intercellular communication promotes metastasis and stemness. In bladder cancer, ELNAT1 transmission via extracellular vesicles promotes lymph node metastasis. In breast cancer, Hsp70 delivery via small extracellular vesicles enhances adriamycin resistance. These functional outcomes link GO:0110077 to clinically important phenotypes such as metastasis, stemness, and therapy resistance.
Regulation by post-translational modifications
In simple terms: Chemical tags on proteins control what gets shipped and where.
Post-translational modifications regulate vesicle-mediated intercellular transport. SUMOylation promotes extracellular vesicle-mediated transmission of the lncRNA ELNAT1 and lymph node metastasis in bladder cancer, providing a direct example of how a modification controls cargo transfer. The transport of ALIX and ESCRT-III to the intercellular bridge during cytokinesis further illustrates that vesicle-related trafficking is tightly regulated in time and space. These regulatory layers determine which cargoes are packaged, when vesicles are released, and which cells receive them.
Key Genes Involved in GO:0110077 vesicle-mediated intercellular transport
The following genes and proteins have been experimentally implicated in vesicle-mediated intercellular transport or in related vesicle-mediated transport processes in cancer and cell biology studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALIX | ESCRT-associated protein transported to the intercellular bridge during cytokinesis | Studied as a component of vesicle-mediated transport machinery |
| ESCRT-III | Membrane remodeling complex involved in vesicle trafficking | Transported to the intercellular bridge during cytokinesis |
| Hsp70 | Stress protein delivered between cells via small extracellular vesicles | Enhances adriamycin resistance in breast cancer |
| ELNAT1 | Long non-coding RNA transmitted via extracellular vesicles | SUMOylation-dependent transmission promotes lymph node metastasis in bladder cancer |
| SUMOylation machinery | Post-translational modification system regulating cargo sorting | Promotes extracellular vesicle-mediated ELNAT1 transmission |
| Vesicle-mediated transport-related genes (cervical cancer signature) | Gene set associated with vesicle-mediated transport | Predicts prognosis, immunotherapy response, and drug sensitivity in cervical cancer |
| Vesicle-mediated transport-related genes (gastric cancer signature) | Gene set associated with vesicle-mediated transport | Prognostic risk markers in gastric cancer |
| Tumor-derived apoptotic extracellular vesicle cargo | Cargo that promotes metastasis and stemness | Studied in lung adenocarcinoma |
| Breast cancer extracellular vesicle cargo | Cargo that reprograms the tumor microenvironment | Studied in breast cancer progression and metastasis |
| Extracellular vesicle membrane proteins | Membrane-associated cargo and signaling molecules | Central to the definition of GO:0110077 |
| Extracellular vesicle lumen proteins | Soluble cargo enclosed within vesicles | Central to the definition of GO:0110077 |
| Extracellular vesicle-associated lncRNAs | Regulatory RNAs transferred between cells | Implicated in metastasis and intercellular communication |
| Extracellular vesicle-associated Hsp70 | Protein cargo modulating drug resistance | Studied in breast cancer therapy resistance |
| ESCRT-associated trafficking proteins | Machinery for vesicle formation and cargo sorting | Relevant to vesicle-mediated transport mechanisms |
| Tumor microenvironment recipient cell factors | Mediators of vesicle cargo effects in recipient cells | Studied in breast cancer progression |
| Metastasis-associated vesicle cargo | Cargo promoting metastatic behavior | Studied in lung and bladder cancer [1,5] |
| Stemness-associated vesicle cargo | Cargo promoting stem-like phenotypes | Studied in lung adenocarcinoma |
| Therapy-resistance-associated vesicle cargo | Cargo modulating drug response | Studied in breast cancer |
How Is vesicle-mediated intercellular transport Regulated?
Vesicle-mediated intercellular transport is regulated at multiple levels, including cargo selection, vesicle biogenesis, release, and uptake. SUMOylation is a key regulatory modification that promotes extracellular vesicle-mediated transmission of the lncRNA ELNAT1 and drives lymph node metastasis in bladder cancer. The transport of ALIX and ESCRT-III to the intercellular bridge during cytokinesis shows that vesicle-related trafficking is coordinated with cell division. In cancer, the composition and functional impact of vesicle cargo are shaped by the tumor context, as seen in breast cancer where extracellular vesicle-mediated transport reprograms the tumor microenvironment and in lung adenocarcinoma where tumor-derived apoptotic extracellular vesicles promote metastasis and stemness. Small extracellular vesicle-mediated Hsp70 delivery in breast cancer further illustrates that vesicle cargo can modulate therapeutic response. These regulatory layers make GO:0110077 a dynamic and context-dependent process.
vesicle-mediated intercellular transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ELNAT1 | Bladder cancer lymph node metastasis | Knockout or overexpression of ELNAT1 in bladder cancer cell lines followed by extracellular vesicle transfer assays |
| Hsp70 | Breast cancer adriamycin resistance | Knockout or overexpression of Hsp70 in breast cancer cells with small extracellular vesicle isolation and drug sensitivity assays |
| ALIX | Cytokinesis and vesicle-mediated transport | Knockout or tagged knock-in of ALIX to track transport to the intercellular bridge |
| ESCRT-III | Cytokinesis and vesicle trafficking | Knockout or point-mutation models to dissect ESCRT-III function in vesicle transport |
| Vesicle-mediated transport-related gene signatures | Cervical cancer prognosis and immunotherapy response | Bioinformatics screening combined with knockout or overexpression validation in cervical cancer models |
Vesicle-mediated intercellular transport in cancer metastasis
Vesicle-mediated intercellular transport is increasingly recognized as a driver of cancer metastasis. In lung adenocarcinoma, tumor-derived apoptotic extracellular vesicle-mediated intercellular communication promotes metastasis and stemness. In breast cancer, extracellular vesicle-mediated transport reprograms the tumor microenvironment to favor progression and metastasis. In bladder cancer, SUMOylation promotes extracellular vesicle-mediated transmission of the lncRNA ELNAT1 and lymph node metastasis. These studies collectively show that vesicle-mediated transport can confer metastatic and stem-like properties on recipient cells.
Vesicle-mediated intercellular transport and therapy resistance
Vesicle-mediated transport can also modulate responses to therapy. Small extracellular vesicle-mediated Hsp70 intercellular delivery enhances adriamycin resistance in breast cancer, demonstrating that vesicle cargo can directly influence drug sensitivity. This finding suggests that targeting vesicle-mediated transport or its cargo could be a strategy to overcome resistance. The broader concept of vesicle signaling as an active communication system supports the idea that therapy resistance can be transmitted between cells via vesicles.
Prognostic and predictive value of vesicle-mediated transport genes
Gene signatures related to vesicle-mediated transport have prognostic and predictive value in multiple cancers. In cervical cancer, vesicle-mediated transport-related genes have been identified for predicting prognosis, immunotherapy response, and drug screening. In gastric cancer, vesicle-mediated transport-related genes have prognostic significance as risk markers. These findings suggest that vesicle-mediated transport-related genes could serve as biomarkers to guide patient stratification and treatment selection.
Vesicle-mediated intercellular transport in cytokinesis and cell division
Vesicle-mediated transport is not limited to intercellular communication in cancer; it also plays roles in basic cell division processes. The transport of ALIX and ESCRT-III to the intercellular bridge during cytokinesis highlights the involvement of vesicle-related trafficking machinery in cell division. This connection broadens the relevance of GO:0110077 beyond oncology and into fundamental cell biology.
From vesicle-mediated intercellular transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate vesicle-mediated transport gene promote metastasis? | Knockout of the gene in cancer cells followed by in vivo metastasis assays [1,5] |
| Does a specific point mutation alter cargo sorting into extracellular vesicles? | Point-mutation knock-in of the gene followed by vesicle cargo analysis |
| Can a tagged vesicle protein be tracked during intercellular transport? | Tagged knock-in of the gene to visualize vesicle trafficking |
| Does overexpression of a vesicle cargo enhance therapy resistance? | Overexpression of the gene in cancer cells followed by drug sensitivity assays |
| Which vesicle-mediated transport genes predict immunotherapy response? | Bioinformatics screening of patient datasets combined with functional knockout validation [4,6] |
| How does SUMOylation regulate vesicle-mediated lncRNA transmission? | Knockout or point mutation of SUMOylation sites followed by extracellular vesicle transfer assays |
How to Study the vesicle-mediated intercellular transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Differential centrifugation | Vesicle enrichment from conditioned media | Isolation of extracellular vesicles for functional studies |
| Nanoparticle tracking analysis | Vesicle size and concentration | Characterization of vesicle preparations |
| Immunoblotting | Presence of vesicle markers and cargo proteins | Validation of vesicle cargo such as Hsp70 |
| Fluorescent tagging and live-cell imaging | Vesicle trafficking and transfer | Tracking ALIX and ESCRT-III to the intercellular bridge |
| Transcriptomic profiling | Gene expression changes in donor or recipient cells | Identifying vesicle-mediated transport-related genes [4,6] |
| Proteomic profiling | Protein cargo composition of vesicles | Discovering vesicle-associated proteins |
| Drug sensitivity assays | Recipient cell response to therapy | Testing whether vesicle cargo enhances resistance |
| Bioinformatics signature analysis | Prognostic and predictive gene signatures | Predicting immunotherapy response and drug sensitivity [4,6] |
Extracellular vesicle isolation and characterization
Studying vesicle-mediated intercellular transport requires robust isolation and characterization of extracellular vesicles. Methods such as differential centrifugation, size-exclusion chromatography, and density gradient separation are commonly used to purify vesicles from conditioned media. Characterization typically involves nanoparticle tracking analysis, electron microscopy, and immunoblotting for vesicle markers. These approaches have been applied in studies of Hsp70 delivery in breast cancer and ELNAT1 transmission in bladder cancer.
Functional transfer assays
Functional transfer assays are used to determine whether vesicle cargo can alter recipient cell behavior. Donor cells are typically labeled or engineered to express a tagged cargo, and vesicles are collected and applied to recipient cells. Readouts include changes in gene expression, signaling, drug sensitivity, and metastatic potential. Such assays have demonstrated that small extracellular vesicle-mediated Hsp70 delivery enhances adriamycin resistance and that extracellular vesicle-mediated ELNAT1 transmission promotes lymph node metastasis.
Omics and bioinformatics approaches
Omics and bioinformatics approaches are essential for identifying vesicle-mediated transport-related genes and signatures. Transcriptomic and proteomic profiling of vesicles and recipient cells can reveal cargo composition and downstream effects. Bioinformatics screening has been used to identify vesicle-mediated transport-related genes for predicting prognosis, immunotherapy response, and drug screening in cervical cancer and as prognostic risk markers in gastric cancer. These methods help prioritize candidate genes for functional validation.
Imaging and tracking of vesicle transport
Imaging approaches allow direct visualization of vesicle-mediated transport. Fluorescent tagging of vesicle proteins and cargo enables tracking of vesicles from donor to recipient cells. The transport of ALIX and ESCRT-III to the intercellular bridge during cytokinesis has been studied using such imaging techniques. Live-cell imaging and super-resolution microscopy can provide spatial and temporal resolution of vesicle release and uptake.
How CRISPR Can Be Used to Study GO:0110077 vesicle-mediated intercellular transport
Knockout
CRISPR knockout is used to eliminate a candidate vesicle-mediated transport gene and assess its causal role. For example, knocking out ELNAT1 or its regulatory machinery can test whether extracellular vesicle-mediated transmission is required for lymph node metastasis in bladder cancer. Knocking out Hsp70 can determine whether small extracellular vesicle-mediated delivery is necessary for adriamycin resistance in breast cancer. Knockout of ALIX or ESCRT-III components can reveal their roles in vesicle trafficking during cytokinesis.
Point Mutation
CRISPR point mutation allows precise modification of specific residues to test their function. This is particularly useful for studying post-translational modification sites, such as SUMOylation sites that regulate extracellular vesicle-mediated ELNAT1 transmission in bladder cancer. Point mutations can also be used to disrupt protein-protein interaction interfaces in ESCRT components and assess effects on vesicle transport.
Knock-in
CRISPR knock-in can introduce tags or reporters to track vesicle proteins and cargo. Tagged knock-in of ALIX or ESCRT-III enables visualization of their transport to the intercellular bridge during cytokinesis. Knock-in of fluorescent reporters into vesicle cargo genes can facilitate tracking of intercellular transfer in real time. These models are valuable for understanding the spatiotemporal dynamics of vesicle-mediated transport.
Overexpression
CRISPR overexpression or cDNA-based overexpression is used to test whether increased levels of a vesicle cargo or machinery component enhance transport or downstream phenotypes. Overexpression of Hsp70 in breast cancer cells can increase small extracellular vesicle-mediated delivery and enhance adriamycin resistance. Overexpression of ELNAT1 or its regulators can promote extracellular vesicle-mediated transmission and metastasis in bladder cancer models. Overexpression studies complement knockout approaches by demonstrating sufficiency.
How EDITGENE Supports vesicle-mediated intercellular transport Research
Researchers studying vesicle-mediated intercellular transport-related genes often need to determine whether a candidate gene is causally involved in cargo sorting, vesicle release, or recipient cell reprogramming. Establishing causality requires precise genetic manipulation, and CRISPR-based models provide the necessary tools to knock out, mutate, tag, or overexpress genes in relevant cell types. By combining these models with vesicle isolation, functional transfer assays, and omics readouts, investigators can move from correlation to mechanism.
Contact EDITGENE today to design your custom CRISPR model for vesicle-mediated intercellular transport research.
Frequently Asked Questions About vesicle-mediated intercellular transport
What is GO:0110077 vesicle-mediated intercellular transport?
GO:0110077 is a biological process in which transported substances are moved in extracellular vesicles between cells, with cargo enclosed in the vesicle lumen or located in the extracellular vesicle membrane.
What genes are involved in vesicle-mediated intercellular transport?
Genes and proteins implicated in this process include ALIX, ESCRT-III, Hsp70, ELNAT1, and SUMOylation machinery, as well as vesicle-mediated transport-related gene signatures identified in cervical and gastric cancers [2,4,5,6,7].
How does vesicle-mediated intercellular transport promote cancer metastasis?
Tumor-derived vesicles can deliver cargo that promotes metastasis and stemness, as shown in lung adenocarcinoma, and can reprogram the tumor microenvironment in breast cancer [1,3].
What is the role of SUMOylation in vesicle-mediated intercellular transport?
SUMOylation promotes extracellular vesicle-mediated transmission of the lncRNA ELNAT1 and lymph node metastasis in bladder cancer.
Can vesicle-mediated transport cause drug resistance?
Yes, small extracellular vesicle-mediated Hsp70 intercellular delivery enhances adriamycin resistance in breast cancer.
What are vesicle-mediated transport-related gene signatures?
These are gene sets associated with vesicle-mediated transport that have prognostic value and can predict immunotherapy response and drug sensitivity, as identified in cervical and gastric cancers [4,6].
How is ALIX involved in vesicle-mediated transport?
ALIX and ESCRT-III are transported to the intercellular bridge during cytokinesis, linking vesicle trafficking machinery to cell division.
What experimental models are used to study vesicle-mediated intercellular transport?
Common models include CRISPR knockout, point-mutation, knock-in, and overexpression cell lines, combined with extracellular vesicle isolation, functional transfer assays, and omics profiling [1,2,4,5,7].
Why is vesicle-mediated intercellular transport important for immunotherapy?
Vesicle-mediated transport-related gene signatures can predict immunotherapy response, suggesting that these genes may influence how tumors respond to immune-based therapies.
How can CRISPR help study vesicle-mediated intercellular transport?
CRISPR knockout, point mutation, knock-in, and overexpression allow researchers to test the causal role of specific genes in vesicle cargo sorting, release, and recipient cell reprogramming [2,5,7].
Conclusion
GO:0110077 vesicle-mediated intercellular transport is a biologically and clinically important process that enables cells to exchange proteins, RNAs, and membrane components via extracellular vesicles. It is implicated in cancer metastasis, stemness, therapy resistance, and tumor microenvironment reprogramming, and vesicle-mediated transport-related gene signatures have prognostic and predictive value in multiple cancers [1,3,4,5,6,7]. Understanding its mechanisms requires precise genetic tools and functional assays. By combining CRISPR knockout, point-mutation, knock-in, and overexpression models with vesicle isolation, imaging, and bioinformatics, researchers can dissect the causal roles of individual genes in this process. EDITGENE provides a comprehensive suite of services to support such studies, from model generation to library screening and data analysis, helping to accelerate discoveries in vesicle-mediated intercellular transport.
References
- 1. He X et al.. 2024. Tumor-derived apoptotic extracellular vesicle-mediated intercellular communication promotes metastasis and stemness of lung adenocarcinoma.. Bioact Mater 36:238-255 PMID: 38481566
- 2. Pust S et al.. 2023. Vesicle-mediated transport of ALIX and ESCRT-III to the intercellular bridge during cytokinesis.. Cell Mol Life Sci 80(8):235 PMID: 37523003
- 3. Brena D et al.. 2022. Extracellular vesicle-mediated transport: Reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis.. Transl Oncol 15(1):101286 PMID: 34839106
- 4. Lou S et al.. 2024. Identification of Vesicle-Mediated Transport-Related Genes for Predicting Prognosis, Immunotherapy Response, and Drug Screening in Cervical Cancer.. Immun Inflamm Dis 12(11):e70052 PMID: 39513664
- 5. Chen C et al.. 2021. SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer.. J Clin Invest 131(8) PMID: 33661764
- 6. Wan Y et al.. 2025. The Prognostic Significance of Vesicle-Mediated Transport-Related Genes as Risk Markers in Gastric Cancer.. J Biochem Mol Toxicol 39(9):e70508 PMID: 40952796
- 7. Hu W et al.. 2021. Small extracellular vesicle-mediated Hsp70 intercellular delivery enhances breast cancer adriamycin resistance.. Free Radic Biol Med 164:85-95 PMID: 33418113
- 8. Chrzanowski W et al.. 2026. Rethinking Extracellular Vesicle Signaling.. Adv Mater 38(20):e22172 PMID: 41811152
